bruno vincenzi
bruno vincenzi
Affiliazione sconosciuta
Email verificata su unicampus.it
TitoloCitata daAnno
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
19652010
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
5642009
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ...
Clinical Cancer Research 9 (8), 2893-2897, 2003
3642003
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ...
Clinical Cancer Research 8 (5), 1080-1084, 2002
3172002
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients
C Raimondi, A Gradilone, G Naso, B Vincenzi, A Petracca, C Nicolazzo, ...
Breast cancer research and treatment 130 (2), 449-455, 2011
2662011
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer
TC Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, G Tonini
Journal of clinical pathology 57 (6), 591-597, 2004
2622004
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
2612008
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
D Santini, U Vespasiani Gentilucci, B Vincenzi, A Picardi, F Vasaturo, ...
Annals of Oncology 14 (10), 1468-1476, 2003
2002003
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in …
D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ...
Clinical Cancer Research 13 (15), 4482-4486, 2007
1922007
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ...
J Clin Oncol 24 (12), 1883-1891, 2006
1772006
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ...
The oncologist 15 (1), 85, 2010
1762010
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
B Vincenzi, D Santini, G Dicuonzo, F Battistoni, M Gavasci, A La Cesa, ...
Journal of interferon & cytokine research 25 (3), 144-151, 2005
1682005
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ...
PloS one 6 (4), 2011
1602011
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
M Caraglia, D Santini, M Marra, B Vincenzi, G Tonini, A Budillon
Endocrine-related cancer 13 (1), 7-26, 2006
1482006
Fever after zoledronic acid administration is due to increase in TNF-α and IL-6
G Dicuonzo, B Vincenzi, D Santini, G Avvisati, L Rocci, F Battistoni, ...
Journal of interferon & cytokine research 23 (11), 649-654, 2003
1432003
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization
A Gradilone, G Naso, C Raimondi, E Cortesi, O Gandini, B Vincenzi, ...
Annals of Oncology 22 (1), 86-92, 2011
1412011
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ...
Annals of Oncology 23 (9), 2313-2318, 2012
1312012
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
D Santini, G Perrone, I Roato, L Godio, F Pantano, D Grasso, A Russo, ...
Journal of cellular physiology 226 (3), 780-784, 2011
1262011
Cetuximab: from bench to bedside
B Vincenzi, A Zoccoli, F Pantano, O Venditti, S Galluzzo
Current cancer drug targets 10 (1), 80, 2010
1252010
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan
F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ...
The pharmacogenomics journal 10 (5), 458-464, 2010
1242010
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20